BioCentury | Mar 11, 2021
Emerging Company Profile

AgomAb: antibodies driving tissue regeneration and recovery

AgomAb parlayed what began as a cancer drug discovery partnership into an antibody program that could drive tissue regeneration and organ recovery.  On Wednesday, the Belgian biotech raised $74 million in a series B round...
BioCentury | Feb 6, 2021
Product Development

Picking vaccine strategies that could hold up to COVID variants

As new mutations to SARS-CoV-2 emerge faster than many countries can vaccinate their populations,  pressure is mounting on vaccine developers to pre-empt the variants before they take hold, let alone are properly characterized. And while...
BioCentury | Feb 6, 2021
Product Development

Incyte continues layering on new opportunities

The next stage of Incyte’s growth strategy is already well under way as the company continues to expand its cancer portfolio and prepares to bring its first dermatology program to market.  Much of the current...
BioCentury | Feb 4, 2021
Product Development

Vaxart falls on mixed Phase I readout for COVID-19 vaccine; plus BMS-Rockefeller mAb cocktail deal and vaccine updates for Sputnik V, Novavax, Bharat-Ocugen and Sinovac

Vaxart Inc. (NASDAQ:VXRT) lost $13.81 (59%) to $9.52 Wednesday on preliminary Phase I data for VXA-CoV2-1. The data showed the vaccine did evoke CD8+ T cell and IgA responses but no detectable serum neutralizing antibodies....
BioCentury | Feb 3, 2021

Abingworth leans into company creation with largest-ever fund at $465M

Strong performance and continued broad interest in life sciences led to Abingworth raising its largest-ever fund, with the trans-Atlantic VC putting more energy into company creation and co-development...
BioCentury | Feb 2, 2021
Product Development

Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas

Immunovant Inc. (NASDAQ:IMVT) lost 42% to $25.08 on Tuesday after announcing it was pausing trials of anti-FCRN mAb IMVT-1401 (batoclimab) due to elevated total cholesterol and LDL signals in the Phase IIb ASCEND GO-2 thyroid...
BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

...The primary substrate for immune complex formation is an excess of the autoantigen galactose-deficient IgA1 (Gd-IgA1).Atacicept...
...for IgAN patients.”He added, “No other compound to date in our diligence has seen such Gd-IgA1...
...a Phase II study of atacicept in IgAN patients conducted by Merck showed a 60% decrease in Gd-IgA1...
BioCentury | Dec 10, 2020
Product Development

Second clinical readout for Evelo oral microbe-based therapy shows reduced severity in atopic dermatitis

Evelo’s Phase Ib readout in atopic dermatitis strengthens the case for its platform of oral microbiome-derived, gut-restricted therapies to modulate systemic immune activity. Evelo Biosciences Inc. (NASDAQ:EVLO)...
BioCentury | Nov 11, 2020
Product Development

Arena sees clear path to atopic dermatitis Phase III for etrasimod despite data that shed $1B in value

As investors dumped Arena’s stock on etrasimod’s Phase IIb miss in atopic dermatitis, the company made its case that serendipitous pharmacodynamic findings and strong data on the registrational endpoint...
BioCentury | Nov 10, 2020
Product Development

Reata, Calliditas make good on renewed interest in kidney disease with Phase III successes

Two renal diseases are on track for their first approvals after a pair of Phase III studies hit primary endpoints, suggesting renewed interest in the therapeutic area is paying off for patients and investors....
Items per page:
1 - 10 of 343